18234229. METHODS FOR SENSITIZING CANCER CELLS TO T CELL-MEDIATED KILLING BY MODULATING MOLECULAR PATHWAYS simplified abstract (DANA-FARBER CANCER INSTITUTE, INC.)
Contents
- 1 METHODS FOR SENSITIZING CANCER CELLS TO T CELL-MEDIATED KILLING BY MODULATING MOLECULAR PATHWAYS
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 METHODS FOR SENSITIZING CANCER CELLS TO T CELL-MEDIATED KILLING BY MODULATING MOLECULAR PATHWAYS - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Potential Applications
- 1.6 Problems Solved
- 1.7 Benefits
- 1.8 Potential Commercial Applications
- 1.9 Possible Prior Art
- 1.10 Unanswered Questions
- 1.11 Original Abstract Submitted
METHODS FOR SENSITIZING CANCER CELLS TO T CELL-MEDIATED KILLING BY MODULATING MOLECULAR PATHWAYS
Organization Name
DANA-FARBER CANCER INSTITUTE, INC.
Inventor(s)
Kai W. Wucherpfennig of Brookline MA (US)
METHODS FOR SENSITIZING CANCER CELLS TO T CELL-MEDIATED KILLING BY MODULATING MOLECULAR PATHWAYS - A simplified explanation of the abstract
This abstract first appeared for US patent application 18234229 titled 'METHODS FOR SENSITIZING CANCER CELLS TO T CELL-MEDIATED KILLING BY MODULATING MOLECULAR PATHWAYS
Simplified Explanation
The present invention is based on the identification of novel biomarkers and methods to sensitize cancer cells to T cell-mediated killing.
- Novel biomarkers identified for sensitizing cancer cells to T cell-mediated killing
- Methods developed to modulate these biomarkers
- Aim to enhance the effectiveness of T cell-mediated killing of cancer cells
Potential Applications
The technology could be applied in:
- Cancer immunotherapy
- Precision medicine for cancer treatment
Problems Solved
The technology addresses the challenge of cancer cells evading T cell-mediated killing.
Benefits
- Improved efficacy of cancer treatment
- Potential for personalized cancer therapy
Potential Commercial Applications
- Pharmaceutical companies for drug development
- Biotechnology companies for research and development
Possible Prior Art
There may be prior art related to biomarkers and cancer immunotherapy, but specific examples are not provided in this context.
Unanswered Questions
How does this technology compare to existing cancer immunotherapies?
The article does not provide a direct comparison to existing cancer immunotherapies.
What are the potential side effects of modulating these biomarkers?
The potential side effects of modulating the identified biomarkers are not discussed in the article.
Original Abstract Submitted
The present invention is based, in part, on the identification of novel biomarkers, and methods of modulate thereof, for sensitizing cancer cells to T cell-mediated killing.
